384 related articles for article (PubMed ID: 25898962)
1. MET Mutation Associated with Responsiveness to Crizotinib.
Waqar SN; Morgensztern D; Sehn J
J Thorac Oncol; 2015 May; 10(5):e29-e31. PubMed ID: 25898962
[No Abstract] [Full Text] [Related]
2. MET-Mutated NSCLC with Major Response to Crizotinib.
Mendenhall MA; Goldman JW
J Thorac Oncol; 2015 May; 10(5):e33-e34. PubMed ID: 25898965
[No Abstract] [Full Text] [Related]
3. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
Jenkins RW; Oxnard GR; Elkin S; Sullivan EK; Carter JL; Barbie DA
Clin Lung Cancer; 2015 Sep; 16(5):e101-4. PubMed ID: 25769807
[No Abstract] [Full Text] [Related]
4. Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification.
Cil I; Zirtiloglu A; Saydam N; Tural D
J BUON; 2017; 22(1):279-280. PubMed ID: 28365967
[No Abstract] [Full Text] [Related]
5. Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
Benderra MA; Aspeslagh S; Postel-Vinay S; Bigot L; De Baere T; Loriot Y; Lacroix L; Massard C; Vassal G; André F; Soria JC
J Thorac Oncol; 2016 Feb; 11(2):e21-3. PubMed ID: 26845121
[No Abstract] [Full Text] [Related]
6. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
Mahjoubi L; Gazzah A; Besse B; Lacroix L; Soria JC
Invest New Drugs; 2016 Jun; 34(3):397-8. PubMed ID: 26892698
[TBL] [Abstract][Full Text] [Related]
7. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
[TBL] [Abstract][Full Text] [Related]
8. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
Shea M; Huberman MS; Costa DB
J Thorac Oncol; 2016 Jul; 11(7):e81-2. PubMed ID: 26845194
[No Abstract] [Full Text] [Related]
9. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
Rabeau A; Rouquette I; Vantelon JM; Taranchon-Clermont E; Mazières J
Rev Mal Respir; 2017 Jan; 34(1):57-60. PubMed ID: 27745897
[TBL] [Abstract][Full Text] [Related]
10. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G
J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444
[No Abstract] [Full Text] [Related]
11. Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.
Li YQ; Song SS; Jiang SH; Zhang XY
Ann Oncol; 2017 Oct; 28(10):2622-2624. PubMed ID: 28961830
[No Abstract] [Full Text] [Related]
12. Response to Crizotinib and Clinical Outcome in ALK-Rearranged Pulmonary Pleomorphic Carcinoma.
Murakami Y; Saka H; Oki M
J Thorac Oncol; 2015 May; 10(5):e28-e29. PubMed ID: 25898961
[No Abstract] [Full Text] [Related]
13. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
Zhang Y; Yin J; Peng F
Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
[No Abstract] [Full Text] [Related]
14. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
[TBL] [Abstract][Full Text] [Related]
15. Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.
Zhang Y; Wang W; Wang Y; Xu Y; Tian Y; Huang M; Lu Y
J Thorac Oncol; 2016 May; 11(5):e59-e62. PubMed ID: 26724472
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.
Pruis MA; Paats MS; Geurts WRR; Dubbink HJ; Dingemans AC
JCO Precis Oncol; 2021 Nov; 5():849-853. PubMed ID: 34994615
[No Abstract] [Full Text] [Related]
17. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma.
Yoshimura K; Karayama M; Inoue Y; Kahyo T; Inui N; Maekawa M; Sugimura H; Suda T
Lung Cancer; 2018 Oct; 124():317-319. PubMed ID: 29573824
[No Abstract] [Full Text] [Related]
19. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
20. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
[No Abstract] [Full Text] [Related]
[Next] [New Search]
